2011;29:4 16. 123. Thompson AM, Hu T, Eshelbrenner CL, et al. Antihypertensive treatment and secondary prevention of cardiovascular disease events among per- sons without hypertension: a meta-analysis. JAMA. 2011;305:913 22. 124. SPRINT Research Group, Wright JT Jr, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103 16. 125. Blood Pressure Lowering Treatment Trialists Collaboration. Blood pres- sure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet. 2014;384:591 8. 126. Kassa B, Boissel J-P, Cucherat M, et al. Treatment of high blood pres- sure and gain in event-free life expectancy. Vasc Health Risk Manag. 2005;1:163 9. 127. Montgomery AA, Fahey T, Ben-Shlomo Y, et al. The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis. J Hypertens. 2003;21:1753 9. 128. van Dieren S, Kengne AP, Chalmers J, et al. Effects of blood pressure lowering on cardiovascular outcomes in different cardiovascular risk groups among participants with type 2 diabetes. Diabetes Res Clin Pract. 2012;98:83 90. 129. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combina- tions improve medication compliance: a meta-analysis. Am J Med. 2007;120:713 9. 130. Yang W, Chang J, Kahler KH, et al. Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives. Curr Med Res Opin. 2010;26:2065 76. 131. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55:399 407. 132. Sherrill B, Halpern M, Khan S, et al. Single-pill vs free-equivalent combi- nation therapies for hypertension: a meta-analysis of health care costs and adherence. J Clin Hypertens (Greenwich). 2011;13:898 909. 133. Muntner P, Einhorn PT, Cushman WC, et al. 